Second-Line Treatment for Lung Cancer

Lung Cancer a dangerous disease but curable with proper guidance. As you regularly reading about lung cancer in this blogs previous posts, also you read about systemic-therapy in “Systemic Therapy for Advance Non-Small Cell Lung Cancer” post. After that you read about First-Line treatment in previous post “First-Line Treatment for Lung Cancer”; now know about Second-Line and Third-Line Treatment.

Second-Line Treatment for Lung Cancer is a systemic-therapy, in which drug or combination of drugs given to the patient after the failure of first-line treatment.

Following drugs options are suggested in second-line treatment patients with nonsquamous cell carcinoma:

  • Docetaxel (Docefrez, Taxotere): is an anti-mitotic chemotherapy drug that is clinically well-established that works by intrusive with cell division.
  • Erlotinib: known Tarceva as a trade name; is used to treat non-small cell lung cancer (NSCLC) by blocking Epidermal Growth Factor Receptor (EGFR) – EGFR is a protein which involved in growth and development of cancer.
  • Gefitinib: known Iressa as a trade name; it also block the growth of Epidermal Growth Factor Receptor (EGFR).
  • Pemetrexed: known Alimta as a trade name. This drug suggested to patients with nonsquamous cell carcinoma; not for patients with squamous cell carcinoma.

Following drugs options are suggested in second-line treatment patients with squamous cell carcinoma:

  • Docetaxel;
  • Erlotinib;
  • Gefitinib.

If first-line treatment with targeted therapy is failed to control the growth of cancer cells for patients with a genetic change to the EGFR gene, chemotherapy or other targeted therapy is recommended.

Patients with a genetic change to the ALK gene who’s cancer goes worse in first-line treatment, chemotherapy or ceritinib (Zykadia) are suggested.

If both first-line treatment and second-line treatment fails; also chemotherapy not recommended; third-line treatment suggested – read about it on post “Third-Line Treatment for Lung Cancer”.

Leave a Reply